Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05237947
Other study ID # NCI-2022-00343
Secondary ID NCI-2022-00343DC
Status Active, not recruiting
Phase Phase 4
First received
Last updated
Start date March 1, 2022
Est. completion date May 31, 2026

Study information

Verified date March 2024
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase IV trial tests whether a single dose of the human papillomavirus (HPV) vaccine works in preventing cervical cancer in young women in Costa Rica. Human papilloma viruses, called HPV, are a group of viruses that very frequently cause infection in both men and women, mainly in the genital organs. There are many types of HPV, and some can cause cancer. The World Health Organization recommends a two-dose schedule for adolescents 9-14 and three doses for individuals 15 years old or older. This study examines whether a single dose of HPV vaccine can reduce the frequency with which women between ages 18-30 become infected with HPV.


Description:

PRIMARY OBJECTIVES: I. To evaluate one dose of nonavalent human papillomavirus (HPV) vaccination compared to no vaccination in the protection against incident HPV16/18 cervical HPV infections that persist 6-months or more in women aged 18 to 30 years who are cervical HPV16/18 deoxyribonucleic acid (DNA) negative prior to and at the time of vaccination. II. To evaluate one dose of bivalent HPV vaccination compared to no vaccination in the protection against incident HPV16/18 cervical HPV infections that persist 6-months or more in women aged 18 to 30 years who are cervical HPV16/18 DNA negative prior to and at the time of vaccination. SECONDARY OBJECTIVES: I. To quantitate the benefit of one dose of HPV vaccination compared to no vaccination in the protection against incident HPV16/18 cervical HPV infections that persist 6-months or more in women aged 18 to 30 years regardless of cervical HPV DNA status at the time of vaccination. II. To estimate the health impact of older-age single-dose HPV vaccination by modeling the number of cervical cancer cases prevented as well as the cost-effectiveness of cervical cancer prevention strategies incorporating vaccination and screening in Costa Rica. III. To evaluate the immunogenicity (absolute levels and stability of serum antibodies) of single dose HPV vaccination in women. IV. For each vaccine separately, to evaluate one dose of HPV vaccination compared to no vaccination in the protection against: IVa. Any new HPV16/18 anal infection that persists 6+ months. IVb. Any new HPV16/18 oral infection that persists 6+ months. IVc. Any new carcinogenic HPV cervical, anal or oral infection detected at a single timepoint and that persists 6+ months. IVd. Any new cervical HPV6/11 infection that persists 6+ months. OUTLINE: Patients are randomized to 1 of 3 arms. ARM I: Patients receive one dose of recombinant human papillomavirus nonavalent vaccine (Gardasil 9) intramuscularly (IM). ARM II: Patients receive one dose of recombinant human papillomavirus bivalent vaccine (Cervarix) IM. ARM III: Patients receive one dose of diphtheria toxoid/tetanus toxoid/acellular pertussis vaccine adsorbed vaccine (Adacel) IM. After completion of study, patients are followed up at 6 and 12 months, and then every 6 months thereafter.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 5000
Est. completion date May 31, 2026
Est. primary completion date May 31, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 30 Years
Eligibility Inclusion Criteria: - INCLUSION CRITERIA AT ENROLLMENT: Female. - INCLUSION CRITERIA AT ENROLLMENT: Aged between 18 and 30 years inclusive. - INCLUSION CRITERIA AT ENROLLMENT: Living in the study area. - INCLUSION CRITERIA AT ENROLLMENT: Able to communicate with study personnel. - INCLUSION CRITERIA AT ENROLLMENT: Willing to participate in the study and sign the informed consent. - INCLUSION CRITERIA AT ENROLLMENT: In good health as determined by a medical history (physical exam will be conducted if necessary per the doctor's criterion. - DEFERRAL CRITERIA AT ENROLLMENT VISIT: The enrollment visit will be deferred (i.e., rescheduled for another date) for participants if: the self-collected cervical sample is not able to be collected. - DEFERRAL CRITERIA AT THE VACCINATION VISIT: The vaccination visit will be deferred (i.e., rescheduled for another date) for participants if: - They have an acute disease that precludes vaccination (though vaccines can be administered to potential participants with a minor illness such as diarrhea and mild upper respiratory infection) - They are receiving immunosuppressive treatment, e.g. corticosteroids - They have received any registered vaccine in the last 15 days. Exclusion Criteria: - EXCLUSION CRITERIA AT ENROLLMENT VISIT: They have been vaccinated against human papillomavirus (HPV). - EXCLUSION CRITERIA AT ENROLLMENT VISIT: They are allergic to yeast or another vaccine components. - EXCLUSION CRITERIA AT ENROLLMENT VISIT: They have a diagnosis of an autoimmune, degenerative, or neurological disease without treatment or adequate control; a progressive or severe neurological disease; a genetic immunodeficiency; or any other serious chronic disease without treatment and / or adequate control that, according to the principal investigator or designee, for which vaccination is contraindicated. - EXCLUSION CRITERIA AT ENROLLMENT VISIT: They have plans to move outside the country in the next six months. - EXCLUSION CRITERIA AT ENROLLMENT VISIT: They refuse or are unable to self-collect the cervical sample. - EXCLUSION CRITERIA AT ENROLLMENT VISIT: They are pregnant. - EXCLUSION CRITERIA AT ENROLLMENT VISIT: They do not have an identification document. - EXCLUSION CRITERIA AT ENROLLMENT VISIT: The clinician determining eligibility in agreement with the principal investigator considers that there is a reason that precludes participation. - EXCLUSION CRITERIA AT VACCINATION VISIT: Between the enrollment and vaccine visit, they have been vaccinated against HPV. - EXCLUSION CRITERIA AT VACCINATION VISIT: Between the enrollment and vaccine visit, they are being evaluated for or have received a diagnosis of: an autoimmune, degenerative, or neurological disease without treatment or adequate control; a progressive or severe neurological disease; a genetic immunodeficiency; or any other serious chronic disease without treatment and/or adequate control, for which vaccination is contraindicated according to the principal investigator or designee. - EXCLUSION CRITERIA AT VACCINATION VISIT: They have plans to move outside the country in the next six months. - EXCLUSION CRITERIA AT VACCINATION VISIT: They refuse the urine pregnancy test. - EXCLUSION CRITERIA AT VACCINATION VISIT: They have a positive urine pregnancy test result. - EXCLUSION CRITERIA AT VACCINATION VISIT: They are pregnant. - EXCLUSION CRITERIA AT VACCINATION VISIT: They refuse or are unable to perform the self-collected cervical sample. - EXCLUSION CRITERIA AT VACCINATION VISIT: The clinician determining eligibility in agreement with the principal investigator considers that there is a reason that precludes participation.

Study Design


Intervention

Biological:
Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
Given IM
Other:
Questionnaire Administration
Ancillary studies
Biological:
Recombinant Human Papillomavirus Bivalent Vaccine
Given IM
Recombinant Human Papillomavirus Nonavalent Vaccine
Given IM

Locations

Country Name City State
Costa Rica Agencia Costarricense de Investigaciones Biomédicas (ACIB) Liberia Guanacaste

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

Costa Rica, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of persistent HPV infection Will estimate the rate of incident persistent infections (i.e. the primary endpoint defined above) in each of the three arms of an ATP cohort and then estimate the two Vaccine Efficacies (VE), comparing each HPV vaccine arm against the control arm. Will require a one-sided p-value of < 0.0125 for statistical significance. The 97.5% confidence intervals for the VE will be calculated by inverting appropriate hypotheses tests. 6-month persistence observed during follow-up
Secondary Benefit of one dose of HPV vaccination compared to no vaccination Will require a one-sided p-value of < 0.0125 for statistical significance. The 97.5% confidence intervals for the VE will be calculated by inverting appropriate hypotheses tests. 6-month persistence observed during follow-up
Secondary Health impact of older-age single-dose HPV vaccination Will require a one-sided p-value of < 0.0125 for statistical significance. The 97.5% confidence intervals for the VE will be calculated by inverting appropriate hypotheses tests. 6-month persistence observed during follow-up
Secondary Immunogenicity (absolute levels and stability of serum antibodies) of single dose HPV vaccination Will report the Geometric Mean Titer (GMT) of the antibodies for each HPV type at the five follow-up visits. 6-month persistence observed during follow-up
Secondary New HPV16/18 anal infection Will report the VE against any new carcinogenic HPV type and against HPV 6/11 in the according to protocol (ATP) cohort using an analysis plan similar to that described for the primary objectives. 6-month persistence observed during follow-up
Secondary New HPV16/18 oral infection Will report the VE against any new carcinogenic HPV type and against HPV 6/11 in the according to protocol (ATP) cohort using an analysis plan similar to that described for the primary objectives. 6-month persistence observed during follow-up
Secondary Carcinogenic HPV cervical, anal or oral infection detected at a single timepoint Will report the VE against any new carcinogenic HPV type and against HPV 6/11 in the according to protocol (ATP) cohort using an analysis plan similar to that described for the primary objectives. 6-month persistence observed during follow-up
Secondary Cervical HPV6/11 infection Will report the VE against any new carcinogenic HPV type and against HPV 6/11 in the according to protocol (ATP) cohort using an analysis plan similar to that described for the primary objectives. 6-month persistence observed during follow-up
See also
  Status Clinical Trial Phase
Completed NCT05458869 - Evaluating the Human Papillomavirus Self-Collection Experience in Individuals Who Have Experienced Sexual Trauma
Completed NCT01932697 - Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer Phase 2
Completed NCT03265743 - HPV Vaccination in Women With Cystic Fibrosis N/A
Completed NCT00543543 - Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Phase 3
Recruiting NCT04226313 - Self-sampling for Non-attenders to Cervical Cancer Screening N/A
Completed NCT06199128 - Efficacy and Safety of Carboxymethyl Beta-glucan and Policarbophil in HPV Positive Patients
Active, not recruiting NCT01824537 - Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study Phase 4
Completed NCT01265212 - Prevalence of Human Papillomavirus in Men Living in the Northern Plains N/A
Terminated NCT01082861 - Efficacy and Immunomodulation Study of Simultaneous Human Papillomavirus/ Hepatitis B (HPV/HBV) Vaccination Phase 4
Unknown status NCT01087164 - Brief Interventions to Increase HPV Vaccine Acceptance in School-based Health Centers N/A
Completed NCT00572832 - Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting N/A
Completed NCT03158220 - Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) Phase 3
Recruiting NCT05210348 - Clinical Evaluation of Detection of High Risk HPV in Urine
Completed NCT05680454 - A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine Phase 1
Completed NCT04133610 - HPVPro Study: Comparison of HPV Detection in Clinician-collected Cervical Swabs and Self-sampled Cervicovaginal Swabs N/A
Completed NCT00988884 - A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005) Phase 3
Not yet recruiting NCT05981807 - HPV Infection, Sexually Transmitted Infections and Anal Dysplasia in the Transgender Population
Recruiting NCT03302858 - A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand Phase 2
Completed NCT01694875 - Clinical Evaluation of the APTIMA® HPV 16 18/45 Genotype Assay on the PANTHER® System N/A
Completed NCT01158209 - An Observational, Epidemiological Study on the Prevalence of Human Papillomavirus Types in Women in Egypt N/A